GlobeNewswire

Colliers Proptech Accelerator Powered by Techstars Announces Call for 2019 Applications

Del

Proptech startups around the world are invited to apply for a position in the 2019 Proptech Accelerator

TORONTO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Colliers International (NASDAQ and TSX:CIGI) has opened applications for the 2019 Colliers Proptech Accelerator Powered by Techstars, seeking enterprising proptech companies that will help lead the industry to the future. This program is part of our focus on strategic innovation and the belief that investments in value-added technology and data can enable our professionals to deliver smarter, more personalized services that make a difference for our clients.

The Colliers Proptech Accelerator Powered by Techstars successfully completed its first class in 2018, with companies representing solutions across the real estate value chain such as commercial datasets for occupiers and investors; office services and tenant engagement; big data, analytics and artificial intelligence; space as a service; marketplaces and space utilization; and, Smart City and Internet of Things. The companies worked with more than 150 mentors from Colliers and the broader industry for the three-month program that culminated with demo day presentations to 600 Colliers people, clients, industry professionals and technology investors.

“We’re energized by the early successes from our class of 2018 and the resulting partnerships and look forward to beginning the 2019 selection process” said Dylan Taylor, CEO Colliers Real Estate Services. “By strategically investing in the right technology solutions and enterprising founders, we can shape the future of our company and the industry. In the words of Peter Drucker, the iconic thinker and founder of modern management who had a great personal influence on Colliers, ‘The best way to predict the future is to create it’ and we believe we are doing just that.”

To learn more and to apply to the Colliers Proptech Accelerator Powered by Techstars, visit the program page.  

“Colliers is a deeply committed partner working to drive change in the commercial real estate industry, making this a unique and special program,” said Ben Liao, managing director, Colliers Proptech Accelerator Powered by Techstars. “We work closely at every step to ensure the startups receive the best and most appropriate mentorship to accelerate their success.”

About Colliers International
Colliers International (NASDAQ, TSX: CIGI) is a leading global real estate services and investment management company. With operations in 68 countries, our 14,000 enterprising people work collaboratively to provide expert advice and services to maximize the value of property for real estate occupiers, owners and investors. For more than 20 years, our experienced leadership team, owning more than 40% of our equity, have delivered industry-leading investment returns for shareholders. In 2018, corporate revenues were $2.8 billion ($3.3 billion including affiliates), with more than $26 billion of assets under management. Learn more about how we accelerate success at corporate.colliers.com, Twitter @Colliers or LinkedIn.

About Techstars
Techstars is the worldwide network that helps entrepreneurs succeed. Techstars founders connect with other entrepreneurs, experts, mentors, alumni, investors, community leaders, and corporations to grow their companies. Techstars operates three divisions: Techstars Startup Programs, Techstars Mentorship-Driven Accelerator Programs, and Techstars Corporate Innovation Partnerships. Techstars accelerator portfolio includes more than 1,600 companies with a market cap of $18.2 Billion. www.techstars.com

For further information, please contact:
Ben Liao, Managing Director, Techstars
Email: Ben.Liao@techstars.com

Carolyn Merchant, Global Director, PR + Communications
Direct: +1 416 324 6405
Email: Carolyn.Merchant@colliers.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Farmako: World's Largest Import Contract for Pharmaceutical Cannabis21.3.2019 15:10:00 CETPressemelding

German Farmako secures 50 tonnes of flowers and oils from Polish company Pharmacann Polska FRANKFURT, March 21, 2019 (GLOBE NEWSWIRE) -- Farmako will import 50 tonnes of pharmaceutical cannabis from Pharmacann Polska into the European market over the next four years. This provides the basis for a reliable supply of pharmaceutical cannabis for millions of patients in the European healthcare system. The company expects a total revenue of several hundred million Euros from the agreed exclusive partnership. Founded in September 2018, Farmako now has grown to 40 employees and is distributing high-quality pharmaceutical cannabis to German pharmacies since March 2019. This is the biggest Cannabis contract to date, and the first big contract without participation of a Canadian LP. Farmako has signed an exclusive and binding agreement to import and distribute 50 tons of pharmaceutical cannabis over four years. Farmako and Pharmacann Polska enter strategic partnership to develop custom tailored

NexOptic Appoints Rich Geruson, Former Lexmark CEO, to Board of Directors21.3.2019 14:00:00 CETPressemelding

VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE: NXO) (OTCQX: NXOPF) (FRANKFURT: E3O1) is pleased to announce that Richard J. (Rich) Geruson has joined its Board of Directors, effective immediately. Mr. Geruson’s experience spans CEO roles at Lexmark International, Phoenix Technologies and VoiceSignal Technologies, and Senior Vice President and executive positions at Nokia, IBM, Toshiba, and McKinsey & Co. As CEO of Lexmark International, a multibillion-dollar imaging technology and solutions company with 10,000 employees, he grew printer sales faster than at any time in the preceding 10 years while simultaneously executing extensive process reengineering, transforming the business from negative EBITDA and high debt to positive multi-hundred-million-dollar EBITDA and a healthy debt profile. While CEO of Phoenix Technologies, he achieved consistently high profit year-over-year for six years straight in

Standard Lithium Announces Closing of $11.4 Million Bought Deal Including Partial Exercise of Over-Allotment Option21.3.2019 14:00:00 CETPressemelding

VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L) is pleased to announce that it has closed its previously announced bought deal offering (the “Offering”), including the partial exercise of the over-allotment option. A total of 11,390,500 units (the “Units”) of the Company were issued at a price of $1.00 per Unit for gross proceeds of $11,390,500. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $1.30 per share, subject to adjustment in certain events, until March 21, 2022. The Units were offered and sold by way of a short form prospectus filed in each of the provinces of ‎Canada, excluding Quebec, and offered and sold elsewhere outside of Canada on a private placement

Crown Bioscience to Present Latest Advancements in Preclinical and Translational Platforms at AACR Annual Meeting 201921.3.2019 13:30:00 CETPressemelding

15 posters present data from novel models to evaluate new cancer therapeutics SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the presentation of 15 scientific posters at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA from March 29 to April 3. The scientific posters highlight the latest advancements in CrownBio’s integrated oncology and immuno-oncology platforms built on the world’s largest and unique experimental model libraries, including patient-derived xenografts (PDXs), innovative humanized mouse models, GEMM, syngeneic mouse tumor homografts, PDX derived organoids (PDXO), and uniquely developed analytic methods. Featured posters will present data from novel models that enable detailed evaluation of new cancer therapeutics, including targeted cancer i

Teledyne CARIS software selected to enable major government project in Africa21.3.2019 12:00:00 CETPressemelding

FREDERICTON, New Brunswick, March 21, 2019 (GLOBE NEWSWIRE) -- Teledyne CARIS™ is pleased to announce they will be delivering a full software solution to the South African Navy Hydrographic Office. The solution, provided through Teledyne CARIS’ official distributor Unique Group, includes software that will be implemented as part of a larger project to be executed by Southern African Shipyards (SAS) where a new hydrographic survey vessel is being built. Three additional survey motor boats are also slated for manufacture, all of which will be equipped with HIPS and SIPS™ to process acquired hydrographic data. During the project, the shore based South African Navy Hydrographic Office will be refurbished and Bathy DataBASE™ (BDB) and Hydrographic Production Database™ (HPD) will be implemented to manage hydrographic data and produce nautical products like paper charts, ENCs and other digital products. The implementation phase is set to commence shortly, and will begin with the installation

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease21.3.2019 12:00:00 CETPressemelding

Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. The decision to stop the trials is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. The recommendation to stop the studies was not based on safety concerns. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. We are incredibly grateful to all the Alzheimer’s disease pa